IDYAIDEAYA BiosciencesRunning, no new patients
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Metastatic Uveal Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 420 (planned)
- Started
- Oct 31, 2023
- Main results expected
- Jan 15, 2027
- Fully finished
- Jan 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:
Measured over: Approximately 5 months
Phase 2 Progression-Free Survival (PFS)
Measured over: Approximately 2 years
Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.
Measured over: Approximately 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05987332 · record last updated 2026-02-17 · checked 2026-11-09 15:36 UTC